BridgeBio publishes corporate presentation outlining rare-disease pipeline and 2026 milestones

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00
  • BridgeBio highlighted Attruby (acoramidis) as approved for ATTR-CM, citing Q1 2026 net product revenue of USD 180.6 million.
  • Presentation cited a 42% reduction in all-cause mortality and cardiovascular hospitalization at month 30 in ATTR-CM.
  • BBP-418 for LGMD2I/R9 listed with a PDUFA date of Nov. 27, 2026; program described as PRV eligible.
  • BridgeBio reported USD 940.2 million in cash, cash equivalents, and marketable securities; raised USD 619.3 million via a convertible senior notes offering.
  • Management expects the company to be significantly cash flow positive in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.